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Abstract
BACKGROUND & AIMS—Standardized instruments are needed to assess the activity of 
eosinophilic esophagitis (EoE), to provide endpoints for clinical trials and observational studies. 
We aimed to develop and validate a patient-reported outcome (PRO) instrument and score, based 
on items that could account for variations in patients’ assessments of disease severity. We also 
evaluated relationships between patients’ assessment of disease severity and EoE-associated 
endoscopic, histologic, and laboratory findings.
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METHODS—We collected information from 186 patients with EoE in Switzerland and the US 
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(69.4% male; median age, 43 years) via surveys (n = 135), focus groups (n = 27), and semi-
structured interviews (n = 24). Items were generated for the instruments to assess biologic activity 
based on physician input. Linear regression was used to quantify the extent to which variations in 
patient-reported disease characteristics could account for variations in patients’ assessment of EoE 
severity. The PRO instrument was prospectively used in 153 adult patients with EoE (72.5% male; 
median age, 38 years), and validated in an independent group of 120 patients with EoE (60.8% 
male; median age, 40.5 years).
RESULTS—Seven PRO factors that are used to assess characteristics of dysphagia, behavioral 
adaptations to living with dysphagia, and pain while swallowing accounted for 67% of the 
variation in patients’ assessment of disease severity. Based on statistical consideration and patient 
input, a 7-day recall period was selected. Highly active EoE, based on endoscopic and histologic 
findings, was associated with an increase in patient-assessed disease severity. In the validation 
study, the mean difference between patient assessment of EoE severity and PRO score was 0.13 
(on a scale from 0 to 10).
CONCLUSIONS—We developed and validated an EoE scoring system based on 7 PRO items 
that assesses symptoms over a 7-day recall period. Clinicaltrials.gov number: NCT00939263.
Keywords
disease activity measurement; esophagus; patient reported outcome; marker
INTRODUCTION
Eosinophilic esophagitis (EoE) is a young disease, as only a little more than two decades 
have passed, since this condition has been recognized as its own standing entity.1,2 Some 
years ago, a panel of international experts defined EoE as “a chronic, immune/antigen-
mediated, esophageal disease characterized clinically by symptoms related to esophageal 
dysfunction and histologically by eosinophil-predominant inflammation”.3 The prevalence 
of EoE is currently estimated at 1/2,000 in the pediatric and adult population of the United 
States and Europe.4,5,6,7 Most adult patients suffer from dysphagia. However, patients may 
also report refractory heartburn and/or chest pain, which is centrally located and does not 
adequately respond to acid-suppressive medications.8,9,10
A standardized and validated patient-reported outcome (PRO) instrument assessing 
symptom severity in patients with EoE is urgently needed to define meaningful endpoints 
for clinical trials and to follow disease evolution in observational studies. Until now, EoE 
symptoms in adult patients have been evaluated in clinical trials using different PRO 
instruments. For example, Alexander et al. used the Mayo Dysphagia Questionnaire 30-Day 
(MDQ-30) version and found that swallowed fluticasone improved histologic 
characteristics, but not symptoms of EoE in adult patients.11 The MDQ-30 version has been 
validated in a group of patients presenting with dysphagia and thoracic pain due to various 
gastrointestinal diseases, but not specifically due to EoE.12 An ad hoc-constructed symptom 
assessment instrument was used by Straumann et al. in a placebo controlled study to 
evaluate the efficacy of budesonide in adult EoE patients.13,14 Dellon et al. developed the 
dysphagia symptom questionnaire (DSQ), a 3-item electronic PRO administered daily to 
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assess the frequency of dysphagia caused by eating solid food and relief strategies during the 
dysphagia episodes.15 This DSQ was evaluated in a group of 35 adolescent and adult EoE 
patients with clinically and histologically active disease.15 Of note, none of these three 
instruments fulfill all the criteria currently required for an EoE PRO instrument. The 
assessment of dysphagia is particularly challenging, as it depends not only on disease 
severity, but also on consistencies of foods consumed, and on behavioral adaptation 
strategies to living with dysphagia. Thus, any PRO instrument assessing dysphagia must 
take these factors into account.
Given the lack of standardized, validated PRO instruments, the results of clinical trials 
performed in EoE cannot be easily compared. This might also explain why different 
therapeutic trials document various degrees of association between patient-reported 
symptoms and endoscopic and histologic findings.11,13,14 The current situation poses a 
major challenge for regulatory approval of EoE therapies.16,17
In this paper, we describe the process of development and validation of a PRO instrument 
for adult EoE patients. The study was carried out in accordance with the US Food and Drug 
Administration (FDA) guidelines.16
PATIENTS AND METHODS
Study overview
The adult EEsAI study was carried out in three phases, which are illustrated in 
supplementary Figure 5. During the 1st phase, a comprehensive list of relevant items to be 
potentially incorporated into the PRO, endoscopy, histology, and blood biomarker 
instruments was generated. During the 2nd phase, the prototypes of standardized instruments 
were evaluated in a first patient group. Data derived from the PRO instrument were used to 
derive a symptom severity score. During the 3rd phase, the PRO instrument and PRO score 
were validated in a second group of adult EoE patients.
Item generation
We first established a conceptual framework for instruments to assess symptoms, behavioral 
adaptations, and biologic activity of adult EoE patients (Figure 1). For the item generation, a 
review of the literature and the existing instruments to assess clinical, endoscopic, 
histologic, and biochemical EoE activity was carried out, and expert opinion was provided 
using the Delphi technique (telephone conferences and emails). The Delphi technique allows 
geographically dispersed experts to reach a consensus on a particular complex task.18 A 
Delphi group of adult EoE gastroenterologists (N = 9), allergists (N = 2), and pathologists 
(N = 2) from Switzerland and the United States contributed a list of items that they thought 
best in reflecting endoscopic [N = 6 items], histologic [N = 7 items], and biochemical 
activity [N = 5 items]).
For the PRO instrument item generation, patient input was obtained by a mixed methods 
approach using open-ended patient symptom surveys (N = 135 patients), focus groups (N = 
27 patients) as well as semistructured patient interviews (N = 24 patients). The qualitative 
methods of the development of the PRO instrument are described in detail in the 
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supplementary section (Appendix 1 includes supplementary Tables 1 to 8 and 
supplementary Figures 1 to 4) according to the consolidated criteria for reporting qualitative 
research guidelines.19,20
Item reduction and formatting of the instruments assessing biologic activity
Delphi group members ranked each provided item assessing biologic EoE activity from 0 
(not important) to 5 (very important). The number of items was then reduced by rank order 
from 7 to 5 items, and from 5 to 3 items for histology and blood biomarkers, respectively. 
The number of items (N = 6) for endoscopy did not change. The generated instruments were 
distributed to the Delphi group, and multiple Delphi rounds were conducted to minimize 
interobserver variability, establish clear definitions and to ensure that the final instruments 
reflect the consensus opinion.
PRO instrument
The EEsAI instruments were developed in such a way that PROs are assessed separately 
from items measuring biologic activity.21,22,23,24 The PRO instrument included items on 
symptom severity and behavioral adaptations, which were recalled over 24 hours, 7 days, 
and 30 days, to determine the optimal recall period.
The PRO instrument contained 5 domains: a general domain to assess sociodemographic 
characteristics, two symptom domains to address symptoms dependent and independent of 
food intake, a co-morbidities domain and a medication domain. The PRO instrument 
consisted of 45 items. The domain addressing symptoms while eating or drinking includes 
items on duration, frequency and severity of dysphagia, time required for meal intake, 
dysphagia upon consuming liquids, and pain when swallowing. The Visual Dysphagia 
Question (VDQ) addressed the severity of dysphagia when consuming food of 8 distinct 
consistencies. The 8 food consistencies and examples of foods to illustrate those 
consistencies were as follows: 1) solid meat (such as steak, chicken, turkey, lamb), 2) soft 
foods (such as pudding, jelly, apple sauce), 3) dry rice or sticky Asian rice, 4) ground meat 
(hamburger, meatloaf), 5) fresh white untoasted bread or similar foods (such as doughnut, 
muffin, cake), 6) grits, porridge (oatmeal), or rice pudding, 7) raw fibrous foods (such as 
apple, carrot, celery), and 8) French fries. The examples were chosen based on foods that are 
consumed in the United States, Europe, and Canada. The behavioral adaptations (avoidance, 
modification and slow eating [AMS] of various foods) were also assessed in the context of 
consuming 8 distinct food consistencies. A domain addressing symptoms independent of 
eating or drinking included items on chest pain, heartburn, and acid regurgitation. The last 
two items were reproduced from the MDQ-30 with the permission of the copyright 
owners.12
Patients were asked to provide a Patient Global Assessment (PatGA) of EoE severity on an 
11-point Likert scale, where a score of 0 is defined as ‘no symptoms’ and a score of 10 is 
defined as ‘most severe symptoms’. The PatGA was used as a main outcome parameter for 
every recall period. The PRO instrument was first created in English. Translation of the 
PRO instrument into German and French was performed in accordance with the World 
Health Organization guidelines for translation and adaptation of instruments.25
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Instruments assessing endoscopic, histologic, and laboratory findings
The instrument for physicians consisted of 5 domains: a general domain for physician and 
patient characteristics, a gastro-esophageal reflux (GERD) domain, an anti-eosinophil 
treatment domain, a blood biomarker domain, and an endoscopy domain. The instrument 
also incorporated the physician global assessment of EoE severity (PGA) item. The PGA 
took into account patients’ symptoms (based on history taking), endoscopic, histological, 
and biochemical findings. The PGA was assessed on an 11-point Likert scale, where a score 
of 0 was defined as ‘inactive EoE’ and a score of 10 was defined as ‘most active EoE’. The 
endoscopy domain of the physician instrument was designed based on the EoE Endoscopic 
Reference Score (EREFS) classification and grading system.26
The histopathology instrument contained three domains: a general domain for pathologists 
and two domains assessing EoE-associated histologic features in the distal and proximal 
esophagus. ‘Distal’ was defined as section of the esophagus 5 cm above the 
gastroesophageal junction, while ‘proximal’ was defined as section spanning the top 1/2 of 
the esophagus.
The detailed overview of the physician and histopathology instruments can be found in 
supplementary Table 9.
Study population
The study was registered on clinicaltrials.gov (NCT00939263) and was approved by local 
institutional review boards and ethics committees. All authors had access to the study data 
and reviewed and approved the final manuscript. Between April, 2011 and December, 2012 
(evaluation group) and May, 2013, and July, 2014 (validation group), EoE patients were 
recruited in 1 ambulatory care clinic and 7 hospitals in Switzerland and the United States. 
Adult EoE patients (≥ 17 years of age) in need of an esophagogastroduodenoscopy (EGD) 
for initial diagnosis, for confirming a suspected diagnosis, or for monitoring previously-
diagnosed EoE were invited to participate in the study. Patients provided informed consent 
to participate in the study. EoE was diagnosed by investigators at all centers using published 
diagnostic criteria.3 EoE patients with concomitant GERD were also included if they were 
under a continued proton-pump inhibitor therapy at the time of EGD. All patients underwent 
a standardized physical examination by a physician. EGD was performed and at least 8 
biopsies were obtained (4 from the proximal and 4 from the distal esophagus). Endoscopic 
findings were assessed according to the endoscopy atlas created by Hirano et al.26 Levels of 
blood eosinophils were also measured. Patients completed the PRO instrument before the 
EGD. Gastroenterologists completed the instrument for physicians, while pathologists 
completed the histopathology instrument.
Histologic evaluation was performed by the local center pathologist. Five-μm sections were 
cut from paraffin blocks and hematoxylin & eosin stained for examination by light 
microscopy. The area of a high power field and percentage of the area covered by tissue 
were noted to allow for calculation of peak eosinophil counts/mm2. To determine the peak 
eosinophil count, at least 5 levels of every esophageal biopsy specimen were surveyed under 
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low power, and the eosinophils in the most densely infiltrated area were counted under high 
power examination.
Construction of the visual dysphagia question and avoidance, modification and slow 
eating scores
The data obtained from the VDQ and AMS items were used to create a composite score. A 
sample calculation of the VDQ and AMS scores is provided in Appendix 2.
Data handling and statistical analysis
Data were double-entered by two researchers into EpiData database (version 3.1, the 
EpiData Association, Odense, Denmark) and imported into Stata (version 13, College 
Station, Texas, USA) for analysis. Descriptive results are presented as frequencies and 
corresponding percentages of the group total or median plus interquartile range (IQR). We 
used multivariable linear regression analysis and analysis of variance (ANOVA) models to 
identify redundant information and to obtain an equation for constructing a PRO score. In 
these analyses, the PatGA was used as the outcome, and responses to specific items in the 
instrument as predictors. These analyses allowed us to quantify the extent to which included 
items explained the variability in PatGA. The variables included in the final models were 
chosen on the basis of their relative contribution to the explanatory power of the models, 
coherence of parameter estimates and expert opinion. We evaluated the fit of the models 
using the coefficient of determination (R2). To validate the EEsAI PRO instrument, a second 
group of adult EoE patients was included, and the EEsAI PRO score was calculated based 
on the regression coefficients. The R2 was calculated to assess the relationship between 
EEsAI PRO score and the PatGA. A Bland-Altman plot was used to evaluate the agreement 
between the calculated EEsAI PRO score and the PatGA.
RESULTS
Patient characteristics
153 and 120 adult EoE patients were recruited for evaluation and validation phase, 
respectively. The characteristics of these patients are shown in Table 1. Age at inclusion, 
sex, ethnicity, and education level were comparable between the two groups. When 
compared to the patients in the evaluation group, the patients in the validation group were 
more likely to have EoE symptom onset > 5 years before inclusion into the study (67.2% vs. 
52.9%), to experience self-reported food allergies (50% vs. 30.1%) and to receive EoE-
specific therapies in the last 12 months before inclusion into the study (85.8% vs. 58.8%); 
however, they were less likely to have concomitant GERD (15% vs. 30.7%) and be treated 
with proton-pump inhibitor therapy (32.5% vs. 55.6%).
Predominant EoE symptoms (evaluation group)
Table 2 illustrates the predominant symptoms of patients in the evaluation group, reported 
over the past 24 hours, 7 days and 30 days. When recalled over the last 24 hours, 7 days, and 
30 days, the median PatGA assessed on the 11-point Likert scale (range 0 – 10) was 1 (IQR 
0 – 3), 2 (IQR 1 – 4) and 2 (IQR 1 – 4), respectively. Forty-one (27.5%), 91 (59.5%), and 
126 (82.4%) patients reported trouble swallowing in the past 24 hours, 7 days and 30 days, 
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respectively. Overall, except for the meal duration, which remained relatively constant over 
the time periods examined, patients were more likely to experience dysphagia and pain 
events with increasing length of the recall period.
Assessing dysphagia severity and behavioral adaptations when ingesting foods of 
different consistencies
The symptoms of patients in the evaluation group were analyzed for a 24-hour, 7-day and 
30-day recall period. The data of the VDQ and AMS recalled over a 7-day recall period are 
shown in supplementary Table 10. Generally, the severity of perceived dysphagia increased 
with increasing food consistency. For instance, 21 (13.7%) patients reported that they 
expected to experience severe difficulties when eating solid meat, and 11 (7.2%) patients 
reported the same when eating foods included in a ‘Raw foods’ category. In contrast, 5 
(3.3%) and 6 (3.9%) patients reported that they expected to experience severe difficulties 
when consuming foods of the ‘Soft foods’ and ‘Grits and porridge’ categories, respectively. 
Increased time required to eat a certain food item was the most common complaint for EoE 
patients. For example, 103 (67.3%) patients experienced this phenomenon when eating solid 
meat, followed by 65 (42.5%) when eating ground meat, and 54 (35.3%) when eating bread. 
Food avoidance and food modification were less frequently reported for ‘soft foods’ and 
were mostly associated with high consistency foods, such as meat, and ‘Raw foods’, such as 
vegetables. Similar trends were observed, when data for the 24-hour and 30-day recall 
periods were analyzed (data not shown).
Choosing the appropriate symptom recall period: patient input
Patients participating in the focus groups (n = 27) were asked to choose the best time period 
to reliably recall their symptoms. The majority of patients indicated that 7 day-period is the 
best recall period (19/27, 70.4%), followed by 14-day (5/27, 18.5%), 30-day (2/27, 7.4%), 
and 24- hour (1/27, 3.7%) periods.
Development of the PRO score
We modeled the PatGA recalled over 24-hour, 7-day and 30-day periods by evaluating its 
strength and significance of association with the items of the PRO instrument. The following 
seven items were chosen for inclusion in the PRO instrument based on their contribution to 
the explanatory power of the models, coherence of parameter estimates and expert opinion: 
frequency of trouble swallowing, duration of trouble swallowing, pain when swallowing, 
VDQ, as well as 3 AMS questions. As the answers to VDQ and 3 AMS items were scored to 
derive VDQ and AMS scores, respectively, the resulting 5 variables were used for the 
purposes of analyses presented below.
Frequency of trouble swallowing, duration of trouble swallowing, severity of pain when 
swallowing, VDQ and AMS scores positively correlated with the PatGA for three recall 
periods. The data for the 7-day recall period are shown in supplementary Figure 6. We used 
multivariable linear regression analysis and ANOVA models to evaluate the contribution of 
chosen PRO variables to the PatGA. The results of these analyses are depicted in Table 3. In 
general, the increasing severity of PRO variables mostly showed a positive and significant 
relationship with the PatGA for three recall periods examined. For example, for the 7-day 
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recall period, if a patient experienced daily episodes of trouble swallowing, the predicted 
PatGA increased by 2.61, when compared to 1.3 and 2.29 for trouble swallowing episodes 
experienced 1 – 3 and 4 – 6 times/week, respectively. If, in addition, the duration of those 
trouble swallowing episodes was > 5 minutes, the predicted PatGA increased by another 
0.53.
Although the contribution of 5 PRO variables to the PatGA was similar, when the 7-day and 
30-day recall periods were examined, the contribution of these variables was quite different, 
when the 24-hour recall period was evaluated. For instance, for patients with a highest VDQ 
score quartile (score ranging from 7.6 to 10 – patients experiencing severe difficulties eating 
various foods), the predicted PatGA increased 6.19 for a 24-hour recall period, when 
compared to the increase of only 1.96 and 1.57 for the 7-day and 30-day recall periods, 
respectively. As such, for a 24-hour recall period, the VDQ score contributed ~ 3 – 4 times 
more to the predicted PatGA, when compared to the same VDQ score for the 7-day and 30-
day recall periods. On the other hand, the coefficients for the highest values of the AMS 
score were quite similar with 2.19 for the 24-hour, 2.15 for the 7-day, and 1.91 for the 30-
day periods.
The regression model with 5 variables of the EEsAI PRO instrument explained 72% (R2 = 
0.72), 67% and 58% of the variability in PatGA for the 24-hour, 7-day and 30-day recall 
periods, respectively. Since R2 can be made artificially high by including a large number of 
independent variables that have an apparent effect purely by chance, only 5 independent 
variables that had a large effect were included into the model. Since the EEsAI PRO score 
for a 24-hour recall period was strongly influenced by a response to the VDQ, and the 
frequency of the events, such as pain and dysphagia, was also the lowest for the 24-hour 
recall period, we judged the 24-hour recall period to be less reliable for assessing EoE 
severity. Based on these statistical considerations and patient input, we concluded that a 7-
day recall period represents the best choice for assessing patient-reported EoE severity by 
the means of the EEsAI PRO score.
Relationship between patient-assessed EoE severity and biologic EoE activity
We observed a positive association between endoscopic/histologic alterations and PatGA, 
which is illustrated by means of box plots in Figure 2. We did not find a correlation between 
PatGA and peripheral blood eosinophil counts (r = 0.045, P = 0.67).
Validation of the score as well as practicability and content validity of the instrument
To validate the PRO score obtained during the evaluation phase, we calculated it for every 
EoE patient recruited in the validation group and compared it with the PatGA. The plot in 
Figure 3A shows that the EEsAI PRO score for the 7-day recall period predicted 65% of the 
variability in PatGA, which closely compares with the 67% of variability in PatGA 
explained by the EEsAI PRO score in the evaluation group. The Bland-Altman plot (Figure 
3B) evaluates the agreement between the calculated EEsAI PRO score and the PatGA. A 
mean difference of only 0.13 between PatGA and EEsAI PRO score was observed. The 
upper and lower 95% limits of agreement were 3.04 and −2.79, respectively. Two versions 
of the validated 7-day EEsAI PRO score are shown in Table 4: 1) the original PRO score 
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that ranges from 0 to 8.52 and the 2) ‘user-friendly’ EEsAI PRO score that ranges from 0 to 
100.
To evaluate the practicability and content validity of the validated EEsAI PRO instrument, 
we again contacted the 27 patients that participated in the focus groups. First, we evaluated 
the time patients needed to complete the EEsAI PRO instrument. When completing the 
instrument for the first time, patients required a median of 8 min (IQR 7 – 9 minutes, range 
4 – 10 min). When asked “How difficult was it for you to complete this questionnaire?”, 
patients responded with a median of 1 (IQR 0 – 2, range 0 – 6; 11-point Likert scale where 0 
stands for ‘no difficulties at all’, 10 stands for ‘very difficult’). To evaluate content validity, 
patients were asked the Likert scale question: “Does this questionnaire measure the 
complaints you have had / you currently have due to EoE?” Patents responded with a 
median of 8 (IQR 7 – 9, range 4 – 10; 10 stands for ‘perfectly’, 0 stands for ‘not at all’).
DISCUSSION
Eosinophilic esophagitis is a young disease, and, so far, no validated PRO instruments 
reliably assessing disease activity have been approved by regulatory authorities in US and 
Europe.
In this article, we describe the process of development and validation of the adult EEsAI 
PRO instrument that assesses EoE symptom severity. We developed the EEsAI PRO 
instrument according to FDA guidelines.16 Patient surveys, focus groups, and 
semistructured interviews were used to gain patient input to inform PRO instrument 
development. The resulting PRO instrument was evaluated in the first group of adult EoE 
patients. As gold-standard, we used patient assessment of disease severity (PatGA) to 
develop the EEsAI PRO instrument score. Based on statistical considerations and expert 
input, seven PRO items were selected. These items explained 67% of the total variability in 
the PatGA over a 7 day recall period. The EEsAI PRO instrument was validated in a second 
group of patients, and these seven items explained 65% of the variability in PatGA.
Assessment of dysphagia is a challenge, because this symptom depends not only on the 
severity of the disease, but also on the consistency of the ingested foods. Moreover, patients 
suffering from dysphagia rapidly develop behavioral adaptation strategies. The EEsAI PRO 
instrument assesses dysphagia caused by eating foods of different consistencies (VDQ) and 
takes into account behavioral adaptation strategies. The food consistencies of the VDQ are 
well-defined, and the foods used to illustrate those consistencies are frequently eaten in 
Western countries. As the VDQ includes items on various food groups, the EEsAI PRO 
instrument can be used to assess dysphagia in individuals with, among others, vegetarian 
dietary patterns, food intolerances, and in patients on elimination diets. Based on patient 
input, the EEsAI PRO instrument is a content-valid measure of EoE symptom severity and 
easy to complete.
PRO must be assessed in a defined recall period, but its choice depends on the following 
factors: 1) intended use of the instrument (conceptual framework), 2) the ability of the 
patient to remember the required information, 3) the extent to which the patient with a 
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certain illness is burdened when completing the instrument, 4) the nature of the disease and 
the symptoms, and 5) the study design.27 The choice of a short recall period may lead to 
underestimation of symptom severity, when symptoms have a day-to-day fluctuation, or else 
may place undue burden on the patient, if patients are too ill to frequently complete the 
questionnaire. However, a long recall period may over- or underestimate the true health 
status of the patient. Based on patient preferences and statistical considerations presented in 
this study, the 7-day symptom recall period appears to be most suitable for this chronic 
condition.
In the recent years, several PRO instruments have been developed to assess EoE symptom 
severity. The Straumann Dysphagia Index does not assess dysphagia caused by eating food 
of different consistencies and does not take into account behavioral adaptations to living 
with dysphagia.13,14 The MDQ-30 Day version assesses dysphagia due to various 
esophageal diseases, but it has not been developed for EoE specifically.11,12 Using the DSQ, 
Dellon et al. recently evaluated dysphagia to solid food in a group of 35 adolescent and adult 
EoE patients.15 However, the term ‘solid food’ was not defined in the manuscript. In our 
study, we noted important differences in dysphagia severity and behavioral adaptations to 
dysphagia when patients consumed ‘solid food’ of different consistencies. For example, 
75% of patients expected to experience dysphagia due to consumption of solid meat, 
whereas only 17% of patients expected to experience dysphagia when eating grits or 
porridge. Standardizing the assessment of dysphagia by ingestion of a defined test meal is 
one way of avoiding the complexities associated with the definition of ‘solid food’. 
However, such an approach may not be entirely practical and may raise ethical concerns 
associated with the exposure of the patients to the risk of food bolus impactions.28 The VDQ 
can be thought of as a ‘hypothetical test meal’ that potentially avoids the ethical issues 
associated with the ingestion of a defined test meal. In contrast to findings reported by 
Dellon et al.15, we found that patients frequently reported behavioral adaptations to 
dysphagia, such as food modification, food avoidance, and slow eating. For example, 67% 
of EoE patients reported eating solid meat slower than other people eating this type of food. 
We conclude that the EEsAI PRO instrument is the first to assess dysphagia caused by 
eating foods of distinct consistencies and also takes into account behavioral adaptations.
We observed a positive relationship between endoscopic and histologic alterations and 
patient-assessed EoE severity. We suspect that patients are to a lesser extent sensitive to 
mild endoscopic/histologic alterations when compared to moderate/severe ones. This 
relative lack of sensitivity to mild EoE alterations may explain why the positive correlations 
between EoE symptom severity and endoscopic and histologic findings have been 
documented in some,13,14,29 but not other studies11,30 in both adult and pediatric patients. 
The observed inconsistencies in the correlations between PRO and biologic items may also 
be related to the fact that dysphagia and behavioral adaptations in these studies has not been 
assessed in the context of the various food consistencies. Lastly, the assessment of 
endoscopic and histologic alterations in adult EoE has not been standardized in these 
studies. The recent work by Hirano et al. represents an important milestone in standardizing 
the assessment of endoscopic alterations in EoE.26 At present, the presumed 
pathophysiological mechanisms leading to EoE symptoms involve mucosal inflammation 
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that is associated with dysmotility and/or mechanical restriction due to subepithelial fibrosis. 
We have yet to assess the relationship between symptom severity as captured by the EEsAI 
PRO instrument and the esophageal compliance that can be measured by the Endolumenal 
Functional Lumen Imaging Probe (EndoFLIP).31,32 For the purposes of clinical trials, it 
seems prudent to include both PRO and biologic endpoints as untreated eosinophil-
predominant esophageal inflammation is associated with the generation of esophageal 
strictures that ultimately lead to symptoms.31,33
Our study has several strengths, but some limitations as well. We present data of the first 
international multicenter study to develop and validate an activity index for adult EoE 
patients. We followed the recommendations of the FDA for PRO instrument development.16 
While the DSQ applies a scoring algorithm that involves giving a discrete arbitrarily-chosen 
value to each item response,15 the scores for individual items of the EEsAI PRO instrument 
are based on the regression coefficients of the linear regression modeling using PatGA (the 
current ‘gold-standard’ for patient-perceived symptom severity) as the outcome. The EEsAI 
PRO instrument is the first EoE-specific instrument designed to assess dysphagia caused by 
eating 8 different food consistencies and behavioral adaptations to living with dysphagia. As 
such, the validated EEsAI PRO instrument can be used to measure EoE symptom severity in 
patients that do not eat certain food categories, such as vegetarians or patients on specific 
elimination diets. The EEsAI PRO instrument is validated, content-valid, and easy to 
complete.
As for limitations, the EEsAI PRO instrument was evaluated and validated for adult patients 
only (≥ 17 years of age). The EEsAI PRO instrument is about to be used in an upcoming 
randomized placebo-controlled clinical trials that will provide data on the responsiveness. 
We also evaluated and validated the PRO instrument for a 24-hour recall period, in case 
completion of the PRO instrument on daily basis might be preferred in certain studies. These 
data will be published elsewhere. The development of an electronic PRO (hand-held device) 
will certainly make the instrument even more ‘user-friendly’.
In summary, we report on the development and validation of the adult EEsAI PRO 
instrument to assess EoE symptom severity over a 7-day recall period. The EEsAI PRO 
instrument is content-valid and is easy to complete. The development and validation of an 
instrument for standardized assessment of EoE symptom severity is a matter of paramount 
importance for guiding clinical decision making and for defining the outcome parameters for 
clinical trials as well as epidemiologic studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FDA US Food and Drug Administration
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Figure 1. 
Conceptual framework for development of EEsAI instruments. The components of the flow 
chart outlined with a dashed line, such as EndoFlip or mucosal biomarkers, were not, as of 
yet, evaluated for the purposes of the EEsAI study.
Abbreviations: EndoFlip®, Endolumenal Functional Lumen Imaging Probe.
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Figure 2. 
The relationship between endoscopic / histologic activity and patient-assessed EoE severity. 
The box contains the 25th – 75th percentile of values, the horizontal line in the middle of the 
box represents the median.
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Figure 3. 
A. The correlation plot between the EEsAI PRO score and the PatGA in the validation 
group. B. The Bland-Altman plot for the agreement between the EEsAI PRO score and the 
PatGA in the validation group. The grey box indicates the 95 % limits of agreement.
Abbreviation: PatGA, patient global assessment; EEsAI, eosinophilic esophagitis activity 
index; PRO, patient-reported outcome.
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Table 1
Patient characteristics.
Evaluation group Validation group
Characteristic Frequency % Frequency %
Number of patients 153 (100.0) 120 (100.0)
Males 111 (72.5) 73 (60.8)
Age at inclusion (median, IQR, range) 38 (29 – 46; 17 – 71) 40.5 (31 – 49; 19 – 80)
Ethnicity
  White 148 (96.7) 114 (95.0)
  Non-white 5 (3.3) 6 (5.0)
Education
  Compulsory schooling 2 (1.3) 1 (0.8)
  Vocational training 38 (24.8) 33 (27.5)
  Upper secondary education 67 (43.8) 54 (45.0)
  University education 46 (30.1) 32 (26.7)
EoE symptoms onset
  1 to 3 months ago 1 (0.7) 0 (0.0)
  4 to 11 months ago 8 (5.2) 2 (1.7)
  1 to 5 years ago 63 (41.2) 38 (31.7)
  more than 5 years ago 81 (52.9) 80 (66.6)
Allergic diseases / Allergies
  Asthma 53 (34.6) 42 (35.0)
  Rhinoconjunctivitis 92 (60.1) 72 (60.0)
  Eczema 18 (11.8) 34 (28.3)
  Food allergy 46 (30.1) 60 (50.0)
Gastro-esophageal reflux disease (GERD) 47 (30.7) 18 (15.0)
Diagnosis established
  Clinically 28 (59.6) 3 (16.7)
  Endoscopically 11 (23.4) 6 (33.3)
  Based on pH-metric studies 1 (2.1) 2 (11.1)
  Clinically and endoscopically 7 (14.9) 5 (27.8)
Concomitant medications
  Proton-pump inhibitors 85 (55.6) 39 (32.5)
  Histamine antagonists (H2-receptor) 7 (4.6) 1 (0.8)
  Histamine antagonists (H1-receptor) 25 (16.3) 18 (15.0)
  Inhaled corticosteroids for asthma 4 (2.6) 4 (3.3)
  β2-adrenergic agonists for asthma 20 (13.1) 2 (1.7)
  Leukotriene receptor antagonists for asthma 4 (2.6) 1 (0.8)
EoE-specific treatments in the last 12 months 90 (58.8) 103 (85.8)
  Hypo-allergenic diets 20 (13.1) 19 (15.8)
  Swallowed topical corticosteroids 65 (42.5) 78 (65.0)
  Esophageal dilation 30 (19.6) 26 (21.7)
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Table 4
EEsAI PRO score for the 7-day recall period. The score based on regression coefficients that ranges from 0 to 
8.52 is shown in column 1. For clinical ease of use, a total of the score based on the regression coefficients 
was set to 100 and values for each category adjusted accordingly. This score is shown in column 2.
Item Score (based on regression coefficients) Score (total set to 100)
Frequency of trouble swallowing Never 0 0
1–3 times/week 1.30 15
4–6 times/week 2.29 27
Daily 2.61 31
Duration of trouble swallowing ≤5 minutes 0 0
>5 minutes 0.53 6
Pain when swallowing No 0 0
Yes 1.27 15
VDQ score 0 0 0
0.1–2.5 1.02 12
2.6–5.0 1.63 19
5.1–7.5 1.81 21
7.6–10.0 1.96 23
AMS score 0 0 0
0.1–2.5 0 0
2.6–5.0 0 0
5.1–7.5 0.77 9
7.6–10.0 2.15 25
Total 8.52 100
Abbreviations: VDQ, visual dysphagia question; AMS, avoidance, modification, and slow eating score.
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